MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies, recently announced the appointment of Dr. Huma Qamar as its Chief Medical Officer (CMO). This addition to the leadership team marks a significant milestone in the company’s pursuit of innovative healthcare solutions.
Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen, expressed his enthusiasm about Dr. Qamar’s appointment, citing her “invaluable contributions” to the company’s clinical team and her instrumental role in advancing a Phase 1/2 gene therapy trial. He also highlighted her efforts in fostering relationships with key stakeholders in the medical and academic communities.
With an illustrious career spanning various prestigious Ivy League institutions such as Yale University, Harvard University, and the University of Pennsylvania, Dr. Qamar brings a wealth of knowledge and experience to Ocugen. Her expertise lies in the development and execution of clinical protocols across all phases, overseeing FDA inspections, and leading medical affairs teams effectively.
Dr. Qamar’s appointment comes at a critical juncture for Ocugen as it navigates the complex terrain of clinical development with an eye toward addressing unmet medical needs through novel gene therapy products. “It’s a pleasure to lead Ocugen’s clinical development at this pivotal time,” Dr. Qamar stated, affirming her commitment to the company’s mission and vision.
Her multifaceted experience spans a broad range of therapeutic areas, including gene and cell therapy, vaccines, oncology, rheumatology, and more, positioning her as a valuable asset in Ocugen’s quest to bring first-in-class candidates to market.
Dr. Prabhavathi Fernandes, Independent Lead Director on Ocugen’s board, underscored Dr. Qamar’s deep understanding of the company’s clinical trials and her strong collaboration with clinical and regulatory teams as fundamental to Ocugen’s success. “I’m confident that her determination and dedication will bring the Company’s first-in-class candidates through the upcoming clinical milestones,” said Dr. Fernandes.
Before joining Ocugen, Dr. Qamar held the position of Senior Vice President, Head of R&D at FSD Pharma, where she demonstrated a steadfast commitment to advancing scientific innovation and pharmaceutical development.
Ocugen’s appointment of Dr. Qamar as CMO signals the company’s readiness to tackle the challenges of clinical development head-on, with an experienced leader at the helm. As Ocugen continues on its path to delivering groundbreaking therapies, Dr. Qamar’s expertise and leadership are expected to play a crucial role in achieving the company’s long-term strategic goals.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.